DK3595665T3 - Dobbelthæmmere af magl og faah - Google Patents

Dobbelthæmmere af magl og faah Download PDF

Info

Publication number
DK3595665T3
DK3595665T3 DK18768237.2T DK18768237T DK3595665T3 DK 3595665 T3 DK3595665 T3 DK 3595665T3 DK 18768237 T DK18768237 T DK 18768237T DK 3595665 T3 DK3595665 T3 DK 3595665T3
Authority
DK
Denmark
Prior art keywords
magl
faah
dual inhibitors
inhibitors
dual
Prior art date
Application number
DK18768237.2T
Other languages
English (en)
Inventor
Cheryl A Grice
Justin S Cisar
Katharine K Duncan
Yu Feng
John J M Wiener
Olivia D Weber
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Application granted granted Critical
Publication of DK3595665T3 publication Critical patent/DK3595665T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK18768237.2T 2017-03-13 2018-03-12 Dobbelthæmmere af magl og faah DK3595665T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762470830P 2017-03-13 2017-03-13
PCT/US2018/022049 WO2018169880A1 (en) 2017-03-13 2018-03-12 Dual magl and faah inhibitors

Publications (1)

Publication Number Publication Date
DK3595665T3 true DK3595665T3 (da) 2024-11-25

Family

ID=63445929

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18768237.2T DK3595665T3 (da) 2017-03-13 2018-03-12 Dobbelthæmmere af magl og faah

Country Status (31)

Country Link
US (4) US10350205B2 (da)
EP (3) EP4335848A3 (da)
JP (5) JP7178375B2 (da)
KR (3) KR102613364B1 (da)
CN (5) CN110709084A (da)
AR (2) AR111271A1 (da)
AU (3) AU2018236161B9 (da)
CA (2) CA3056076A1 (da)
CL (1) CL2019002583A1 (da)
CO (1) CO2019009932A2 (da)
DK (1) DK3595665T3 (da)
EA (1) EA201991898A1 (da)
EC (1) ECSP19066721A (da)
ES (1) ES2994239T3 (da)
FI (1) FI3595665T3 (da)
HR (1) HRP20241558T1 (da)
HU (1) HUE069115T2 (da)
IL (3) IL301334B2 (da)
LT (1) LT3595665T (da)
MX (1) MX2022006862A (da)
NZ (4) NZ756915A (da)
PL (1) PL3595665T3 (da)
PT (1) PT3595665T (da)
RS (1) RS66192B1 (da)
SA (2) SA519410101B1 (da)
SG (1) SG11201908159QA (da)
SI (1) SI3595665T1 (da)
SM (1) SMT202400468T1 (da)
TW (2) TWI874919B (da)
WO (1) WO2018169880A1 (da)
ZA (1) ZA201905934B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN110709084A (zh) * 2017-03-13 2020-01-17 阿比德治疗公司 双重magl和faah抑制剂
CN118561814A (zh) * 2018-09-13 2024-08-30 细胞基因公司 结晶(r)-2-甲基-4-(3-(三氟甲氧基)苄基)哌嗪-1-甲酸5-氨基甲酰基吡啶-3-基酯、其组合物及使用方法
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
JP2023158387A (ja) * 2022-04-18 2023-10-30 株式会社三洋物産 遊技機
JP2023158388A (ja) * 2022-04-18 2023-10-30 株式会社三洋物産 遊技機
JP2023158385A (ja) * 2022-04-18 2023-10-30 株式会社三洋物産 遊技機

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527212A (ja) 2003-06-12 2006-11-30 ノボ　ノルディスク　アクティーゼルスカブ ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート
MXPA05013226A (es) * 2003-06-12 2006-03-09 Novo Nordisk As Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
JP2006088075A (ja) * 2004-09-27 2006-04-06 Kubota Corp 脱臭装置
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
JP2008533155A (ja) 2005-03-18 2008-08-21 インスティテュート フォー ケミカル ジェノミックス アルファへリックス模倣剤および線維症の治療に関する方法
US8772318B2 (en) 2008-11-14 2014-07-08 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
US8461159B2 (en) * 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
US20120083476A1 (en) * 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US20130030000A1 (en) * 2010-01-28 2013-01-31 Chobanian Harry R Pharmaceutical compositions for the treatment of pain and other indications
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JP2013147430A (ja) * 2010-04-28 2013-08-01 Astellas Pharma Inc 夜間頻尿の予防又は治療剤
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
CA2891926A1 (en) 2012-11-20 2014-05-30 Merial, Inc. Anthelmintic compounds and compositions and method of using thereof
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
MX2015017961A (es) 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
WO2015116774A1 (en) * 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
HK1249101A1 (zh) * 2015-07-31 2018-10-26 辉瑞公司 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
CN110709084A (zh) 2017-03-13 2020-01-17 阿比德治疗公司 双重magl和faah抑制剂

Also Published As

Publication number Publication date
CA3299704A1 (en) 2026-03-02
TW202346280A (zh) 2023-12-01
IL311446B2 (en) 2025-03-01
KR102613364B1 (ko) 2023-12-14
US11129827B2 (en) 2021-09-28
EP3595665B1 (en) 2024-08-28
JP7440572B2 (ja) 2024-02-28
JP2024056887A (ja) 2024-04-23
JP7178375B2 (ja) 2022-11-25
SI3595665T1 (sl) 2025-03-31
SMT202400468T1 (it) 2025-01-14
IL311446B1 (en) 2024-11-01
EP4335848A2 (en) 2024-03-13
JP2022141692A (ja) 2022-09-29
LT3595665T (lt) 2024-12-10
EP4424683A3 (en) 2024-11-06
EP4424683A2 (en) 2024-09-04
SA519410101B1 (ar) 2024-01-28
NZ796461A (en) 2026-02-27
NZ756915A (en) 2023-03-31
RS66192B1 (sr) 2024-12-31
IL269119B2 (en) 2023-08-01
AU2022203557B2 (en) 2023-05-18
PT3595665T (pt) 2024-11-21
SG11201908159QA (en) 2019-10-30
IL301334A (en) 2023-05-01
CO2019009932A2 (es) 2020-01-17
JP7781660B2 (ja) 2025-12-08
US12318383B2 (en) 2025-06-03
TWI874919B (zh) 2025-03-01
CA3056076A1 (en) 2018-09-20
WO2018169880A1 (en) 2018-09-20
BR112019018879A2 (pt) 2020-04-14
IL301334B2 (en) 2024-08-01
AU2018236161A1 (en) 2019-09-26
HUE069115T2 (hu) 2025-02-28
KR20230173732A (ko) 2023-12-27
CN117510468A (zh) 2024-02-06
AU2023204293A1 (en) 2023-07-27
NZ797702A (en) 2026-03-27
PL3595665T3 (pl) 2025-01-13
IL301334B1 (en) 2024-04-01
AU2018236161B2 (en) 2022-03-24
CL2019002583A1 (es) 2020-05-15
KR20190130597A (ko) 2019-11-22
JP2020511536A (ja) 2020-04-16
EP3595665A4 (en) 2020-08-19
ES2994239T3 (en) 2025-01-21
JP2026035720A (ja) 2026-03-04
HRP20241558T1 (hr) 2025-03-28
AU2022203557A1 (en) 2022-06-16
CN117466868A (zh) 2024-01-30
US20190282568A1 (en) 2019-09-19
SA523450367B1 (ar) 2024-11-21
EA201991898A1 (ru) 2020-02-07
TWI797111B (zh) 2023-04-01
FI3595665T3 (fi) 2024-11-18
CN110709084A (zh) 2020-01-17
TW201837028A (zh) 2018-10-16
JP2022068197A (ja) 2022-05-09
US20180256566A1 (en) 2018-09-13
US20250262205A1 (en) 2025-08-21
AR125457A2 (es) 2023-07-19
IL269119A (en) 2019-11-28
EP3595665A1 (en) 2020-01-22
US20210386734A1 (en) 2021-12-16
CN118271288A (zh) 2024-07-02
IL311446A (en) 2024-05-01
MX2022006862A (es) 2022-07-11
ZA201905934B (en) 2022-07-27
NZ797704A (en) 2026-02-27
KR20250016458A (ko) 2025-02-03
CN117736178B (zh) 2025-03-21
IL269119B1 (en) 2023-04-01
CN117736178A (zh) 2024-03-22
AR111271A1 (es) 2019-06-26
US10350205B2 (en) 2019-07-16
AU2018236161B9 (en) 2022-03-31
ECSP19066721A (es) 2019-09-30
EP4335848A3 (en) 2024-06-19
KR102756049B1 (ko) 2025-01-21

Similar Documents

Publication Publication Date Title
DK4480953T3 (da) Tyk2-hæmmere og anvendelser deraf
DK3897833T3 (da) Hæmmere af APOL1 og fremgangsmåder til anvendelse heraf
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3661921T3 (da) Selektive hæmmere af nlrp3-inflammasom
DK3667980T3 (da) Indikation og modtagelse af ressourceposition
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3259253T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
EP3761992A4 (en) ARGINASE INHIBITORS
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3452485T3 (da) Arginasehæmmere og deres terapeutiske anvendelser
DK3606519T3 (da) ASK1-inhibitorforbindelser og anvendelser deraf
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3746446T3 (da) PRC2-inhibitorer
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
DK3122359T3 (da) Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf